Semaglutide and Tirzepatide are two new GLP-1-based medications used for the treatment of type 2 diabetes and obesity.
Semaglutide has demonstrated superior effects in reducing HbA1c levels and promoting weight loss. Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, has also been approved by both the U.S. FDA and the European EMA for the treatment of type 2 diabetes.
Efficacy
Both semaglutide and tirzepatide can significantly reduce HbA1c levels in patients with type 2 diabetes, thus improving blood glucose control.
In terms of weight loss, tirzepatide generally shows better results compared to semaglutide.
Cardiovascular Risk
Semaglutide has shown cardiovascular benefits in the SUSTAIN-6 trial, including reduced risks of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Tirzepatide’s cardiovascular effects require further study, particularly the results from the SURPASS-CVOT trial.
Drug Approvals
Semaglutide has been approved as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Tirzepatide has been approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity.
Administration
Both semaglutide and tirzepatide are typically administered via subcutaneous injection.
Semaglutide also has an available oral formulation.
Post time: Jul-08-2025